Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 178.95 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $4.210 million which missed the analyst consensus estimate of $10.883 million by 61.32 percent. This is a 95.04 percent decrease over sales of $84.929 million the same period last year.